UBS Maintains Buy on SI-BONE, Raises Price Target to $25
UBS analyst Patrick Wood maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $24 to $25.
Read original at benzingaStocks · News reference
SI-BONE Q2 EPS $(0.09) Beats $(0.15) Estimate, Sales $56.010M Beat $55.335M Estimate
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.15) by 40 percent. This is a 35.71 percent increase over losses of $(0.14) per share from the same
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 8:10 PM
- Checked
- Aug 3, 2026, 8:10 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Truist Securities Reiterates Buy on SI-BONE, Raises Price Target to $23
Truist Securities analyst Richard Newitter reiterates SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $21 to $23.
Read original at benzingaTD Cowen Maintains Buy on SI-BONE, Raises Price Target to $20
TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $18 to $20.
Read original at benzingaSI-BONE Raises FY2026 Sales Guidance from $230.000M-$233.000M to $231.000M-$233.000M vs $231.775M Est
SI-BONE (NASDAQ:SIBN) raises FY2026 sales outlook from $230.000 million-$233.000 million to $231.000 million-$233.000 million vs $231.775 million estimate.
Read original at benzinga